Controversies in clinical trials in proton radiotherapy: The present and the future

Seminars in Radiation Oncology

Volumn 23, Issue 2, 2013, Pages 127-133

  Miller, Robert C ^a,b   Lodge, Mark ^c   Murad, Mohammad Hassan ^a   Jones, Bleddyn ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INTERNATIONAL NETWORK FOR CANCER TREATMENT AND RESEARCH   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; EVIDENCE BASED MEDICINE; EYE TUMOR; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; METASTASIS; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIOBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RELATIVE BIOLOGIC EFFECTIVENESS; SARCOMA; TISSUES; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; FORECASTING; HUMANS; NEOPLASMS; ORGANS AT RISK; PHOTONS; PROTON THERAPY; RADIATION ONCOLOGY; RADIOMETRY; RADIOTHERAPY DOSAGE;

EID: 84875262179     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.11.004     Document Type: Article

References (55)

1. Suit H., Kooy H., Trofimov A., et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol 2008, 86:148-153.
2. Brada M., De Ruysscher D., Pijls-Johannesma M. In reply. J Clin Oncol 2008, 26:2592-2593.
3. Hofmann B. Fallacies in the arguments for new technology: The case of proton therapy. J Med Ethics 2009, 35:684-687.
4. Adner R., Levinthal D.A. The emergence of emerging technologies. Calif Manag Rev 2002, 45:50-66.
5. Utterback J.M. Invasion of stable business by radical innovation. Mastering the Dynamics of Innovation: How Companies Can Seize Opportunities in the Face of Technological Change 1994, Harvard Business Press, Boston. J.M. Utterback (Ed.).
6. PTCOG: Centers in operation, 2012, Cited July 27, 2012. http://ptcog.web.psi.ch/ptcentres.html.
7. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
8. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol 2010, 95:23-31.
9. Goitein M., Cox J.D. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 2008, 26:175-176.
10. Neoptolemos J.P., Stocken D.D., Friess H., et al. A Randomized Trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
11. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
12. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008, 26:3582-3589.
13. Jones B., Dale R.G., Gaya A.M. Linear quadratic modeling of increased late normal-tissue effects in special clinical situations. Int J Radiat Oncol Biol Phys 2006, 64:948-953.
14. Jones B. The potential clinical advantages of charged particle radiotherapy using protons or light ions. Clin Oncol 2008, 20:555-563.
15. Miller R.C., Schwartz D.J., Sloan J.A., et al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: A phase III double-blind, Randomized Trial from the north central cancer treatment group N06C4. Int J Radiat Oncol Biol Phys 2011, 79:1460-1466.
16. Hall E.J., Wuu C.S. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003, 56:83-88.
17. Kry S.F., Salehpour M., Followill D.S., et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005, 62:1195-1203.
18. Wolden S.L., Lamborn K.R., Cleary S.F., et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998, 16:536-544.
19. Bokemeyer C., Schmoll H.J. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995, 13:283-292.
20. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy?. A Crit Rev Radiother Oncology 2009, 91:4-15.
21. Hull M.C., Morris C.G., Pepine C.J., et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290:2831-2837.
22. Newhauser W.D., Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 2011, 11:438-448.
23. Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo simulations. Phys Med Biol 2012, 57:99-117.
24. Bert C., Durante M. Motion in radiotherapy: Particle therapy. Phys Med Biol 2011, 56:99-117.
25. Palta J. Perils of proton radiotherapy. Presented at the American Association of Physicists in Medicine, "A Symposium on the Perils and Promise of Proton Radiotherapy," May 9, 2009, Baltimore, MD.
26. Jones B., Wilson P., Nagano A., et al. Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma. Br J Radiol 2012, 85:e912-e918.
27. Paganetti H., Niemierko A., Ancukiewicz M., et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 2002, 53:407-421.
28. Carabe-Fernandez A., Dale R.G., Jones B. The incorporation of the concept of minimum RBE (RBEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol 2007, 83:27-39.
29. Jones B., Underwood T.S., Carabe-Fernandez A., et al. Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol 2011, 84(Spec issue 1). S11-SS8.
30. Tepper J.E. Protons and parachutes. J Clin Oncol 2008, 26:2436-2437.
31. Lodge M., Pijls-Johannesma M., Stirk L., et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007, 83:110-122.
32. De Ruysscher D., Mark Lodge M., Jones B., et al. Charged particles in radiotherapy: A 5-year update of a systematic review. Radiother Oncol 2012, 103:5-7.
33. Ashcroft R. Equipoise, knowledge and ethics in clinical research and practice. Bioethics 1999, 13:314-326.
34. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics 1995, 9:127-148.
35. Freedman B. Equipoise and the Ethics of Clinical Research. N Engl J Med 1987, 317:141-145.
36. Introducing new treatments and technologies into the clinic. J Clin Oncol 2008, 26:2425.
37. Glatstein E., Glick J., Kaiser L., et al. Should randomized clinical trials be required for proton radiotherapy?. An alternative view. J Clin Oncol 2008, 26:2438-2439.
38. Lewis B.E. On equipoise and emerging technologies. J Clin Oncol 2008, 26:2590.
39. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
40. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294:1233-1239.
41. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32:3-12.
42. Study of Hypo-fractionated Proton Radiation for Prostate Cancer, 2012 National Institutes of Health, Cited 25 July, 2012. http://clinicaltrials.gov/show/NCT01230866.com.
43. Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate, 2012 National Institutes of Health, Cited July 25, 2012. http://clinicaltrials.gov/show/NCT01492972.
44. Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy. (IMRT) Trial, 2012 National Institutes of Health, Cited 25 July, 2012. http://clinicaltrials.gov/show/NCT01512589.
45. Combs S.E., Kieser M., Rieken S., et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The Cleopatra trial. BMC Cancer 2010, 10:478.
46. Nikoghosyan A.V., Rauch G., Münter M.W., et al. Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer 2010, 10:606.
47. Prospective Assessment of Quality of Life. (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-Central Nervous System (Non-CNS) Malignancies, 2012 National Institutes of Health, Cited 25 July, 2012. http://clinicaltrials.gov/ct2/show/NCT01115777?term=proton+pediatric&rank=10.
48. Registry Study for Proton Therapy Outcomes. 2012 US National Institutes of Health, Cited July 25, 2012. http://ClinicalTrials.gov/show/NCT01255748.
49. Kuhlthau K.A., Pulsifer M.B., Yeap B.Y., et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol 2012, 30:2079-2086.
50. Balshem H., Helfand M., Schünemann H.J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64:401-406.
51. Terasawa T., Dvorak T., Ip S., et al. Systematic review: Charged-particle radiation therapy for cancer. Ann Intern Med 2009, 151:556-565.
52. Vikram B. NCI perspective on proton therapy, American Association of Physicists in Medicine. Presented at the American Association of Physicists in Medicine, "A Symposium on the Perils and Promise of Proton Radiotherapy," May 9, 2009, Baltimore, MD.
53. Guyatt G.H., Oxman A.D., Sultan S., et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011, 64:1311-1316.
54. Gandhi G.Y., Murad M.H., Fujiyoshi A., et al. Patient-important outcomes in registered diabetes trials. JAMA 2008, 299:2543-2549.
55. Mullins C.D., Abdulhalim A.M., Lavallee D.C. Continuous patient engagement in comparative effectiveness research. JAMA 2012, 307:1587-1588.